The primary goal of the Vector Core is to provide participating investigators with the reagents and expertise necessary to utilize various gene delivery systems, both viral and non-viral vectors, in their proposed projects. Broad capabilities must be offered as support to investigative efforts because no single viral vector is completely adequate to satisfy the many technical hurdles which may be encountered in attempting gene therapy for cystic fibrosis. For this reason, the Vector Core will also work closely with projects involved in the development of novel virus- based vectors. Specifically, this Vector Core will provide the following services: l) Consultation to participating investigators who are using specific recombinant systems for gene delivery; 2) Maintenance and distribution of available viral vectors and plasmids with relevant supporting information; 3) Testing and characterization of all vectors provided to investigators for specific research projects; and 4) Providing investigators with all tissue culture and cells required for hybrid virus production. Therefore, the Vector Core is a critical and essential component of the program project and will have a major impact on the success of the various research projects involved. In addition, the centralized service provided by the Vector Core will avoid unnecessary duplication of equipment and supplies, and will also assure better quality control and efficient productivity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051818-07
Application #
6320860
Study Section
Project Start
2000-04-01
Project End
2001-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
2000
Total Cost
$255,866
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Goudy, Kevin S; Johnson, Mark C; Garland, Alaina et al. (2011) Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J Immunol 186:3779-86
Li, Wuping; Zhang, Liqun; Wu, Zhijian et al. (2011) AAV-6 mediated efficient transduction of mouse lower airways. Virology 417:327-33
Zhang, Liqun; Collins, Peter L; Lamb, Robert A et al. (2011) Comparison of differing cytopathic effects in human airway epithelium of parainfluenza virus 5 (W3A), parainfluenza virus type 3, and respiratory syncytial virus. Virology 421:67-77
Johnson, Jarrod S; Gentzsch, Martina; Zhang, Liqun et al. (2011) AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog 7:e1002053
Johnson, Jarrod S; Li, Chengwen; DiPrimio, Nina et al. (2010) Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 84:8888-902
Kwilas, Anna R; Yednak, Mark A; Zhang, Liqun et al. (2010) Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro. J Virol 84:7770-81
Mitchell, Angela M; Nicolson, Sarah C; Warischalk, Jayme K et al. (2010) AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 10:319-340
Zhang, Liqun; Limberis, Maria P; Thompson, Catherine et al. (2010) ?-Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors. Hum Gene Ther 21:1657-64
Li, C; Hirsch, M; Carter, P et al. (2009) A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther 16:43-51
Limberis, Maria P; Vandenberghe, Luk H; Zhang, Liqun et al. (2009) Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 17:294-301

Showing the most recent 10 out of 36 publications